Eli Lilly and Company NYSE: LLY p. farmaceutyczny, największy wytwórca i dystrybutor leków stosowanych w psychiatrii

[slayer74]

Eli Lilly Stock Rockets To Record As Alzheimer's Drug Improves Cognition

Eli Lilly stock rocketed to a record high Monday after the pharmaceutical company said its experimental drug slowed cognitive decline in Alzheimer's disease.

In a Phase 2 study, the potential Alzheimer's treatment, called donanemab, slowed clinical decline by 32% relative to a placebo, Eli Lilly (LLY) said in a news release. Importantly, Lilly's drug targets a form of beta amyloid, similar to Biogen's (BIIB) late-stage drug, aducanumab.

"We are extremely pleased about these positive findings for donanemab as a potential therapy for people living with Alzheimer's disease, the only leading cause of death without a treatment that slows disease progression," Mark Mintun, Lilly's vice president of pain and neurodegeneration, said in a written statement.

In premarket trading on the stock market today, Eli Lilly stock surged 13.6% near 189.

https://www.investors.com/news/technolo ... e-decline/

[slayer74]

How Jim Cramer Is Approaching Eli Lilly Alzheimer's Drug Trial Results

Eli Lilly's (LLY) - Get Report mixed data from its Alzheimer's drug trial disappointed Wall Street.

TheStreet's Martin Baccardax noted that Eli Lilly said that donanemab, an investigational antibody, showed a 32% reduction in a composite measure of cognition and daily function in trial patients suffering early symptomatic Alzheimer's disease following Phase 2 trials. Eli Lilly had said on January 11 that the 32% decline rate, compared to placebo, was 'statistically significant' and met the primary endpoint of phase 2 'Trailblazer' ALZ study.

"Given our conversations with investors when the data first came out, it was clear that expectations were relatively high, which seemed strange to us given the lack of the detailed data and the continuous disappointments in the AD space," said SVB Leerink analyst Marc Goodman. "Given our critical view of the full data set, we do think that the totality of the TRAILBLAZER-ALZ data is still supportive of the anti-Abeta hypothesis, given the significant Abeta clearance and consistently positive trend across several important endpoints, but demonstrating correlation with cognitive endpoints with a prespecified endpoint will still be a challenge."

https://www.thestreet.com/video/jim-cra ... ults-stock

[slayer74]

Eli Lilly (NYSE:LLY) stock fell 3.9% after the drugmaker posted a 7% fall in quarterly profit, due to higher spending on research and development of treatments including Covid-19 drugs.

[slayer74]

Eli Lilly (NYSE:LLY) stock fell 1.9% after the drugmaker missed quarterly profit expectations, hit by weaker sales of its Covid-19 therapies as vaccinations ramped up.

[slayer74]

ŚRODA, 4 SIERPNIA 2021
Eli Lilly (LLY)
Eli Lilly to firma produkująca leki, której data założenia sięga 1876 rok. Należy do największych firm farmaceutycznych na świecie z łączną kapitalizacją rynkową, która wynosi blisko 250 mld. $ i zatrudnia w sumie 35 000 pracowników. Firma była pierwszym koncernem produkującym penicylinę na skalę przemysłową, a obecnie jest największym wytwórcą i dystrybutorem leków stosowanych w psychiatrii.

Jako firma rozwinięta dzieli się swoimi zyskami z akcjonariuszami w formie dywidendy, ale ze względu na najwyższą wycenę fundamentalną w historii tej spółki (w oparciu o zyski), dywidenda ta jest ponadprzeciętnie niska i wynosi 1,33%, przeznaczając na nią niecałe 50% wypracowanych zysków.

Według oczekiwań, spółka w przyszłości będzie rosnąć szybciej niż dotychczas, co zawdzięczać można głównie temu, że w czerwcu amerykańska Agencja ds. Żywności i Leków (FDA) przyznała przełomowe oznaczenie terapeutyczne dla leku na Alzheimera - Donanemab, co może przyspieszyć proces jego zatwierdzania. Mimo tego, uważam że nawet w przypadku dużego sukcesu finansowego produktu (i również medycznego sukcesu), aktualna wycena jest mocno przesadzona.

Patrząc od strony fundamentalnej w ujęciu wyceny akcje nie wyglądają na to aby przy tych poziomach były dobre do inwestycji. Jednak od strony technicznej sytuacja jest dużo lepsza - mamy stabilny trend wzrostowy, korekty rzadko sięgają 20% i to oznacza, że patrząc technicznie, można to wykorzystać aby zarobić w ujęciu tradingowym. Jeśli miałbym się zdecydować na zakup długoterminowy, to rozważyłbym wejście dopiero po wyraźnym spadku wyceny, a to przy obecnych wynikach finansowych, oznaczałoby spadek kursu akcji o ponad 50%. Więcej danych do spółki wraz z wynikami finansowymi z minionej dekady, poniżej:

https://www.pamietnikgieldowy.pl/2021/0 ... y-lly.html

[slayer74]

Eli Lilly hikes dividend by 15.3 percent. $LLY

[slayer74]

Novo Nordisk shares slump on obesity drug supply challenges

COPENHAGEN (Reuters) – Novo Nordisk shares fell 16% on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States.

COPENHAGEN (Reuters) -Novo Nordisk shares fell as much as 16% on Monday after the Danish drugmaker was hit by U.S. supply issues for its new obesity drug as it seeks to establish a market foothold before the launch of a rival drug by Eli Lilly.

https://www.fxempire.com/news/article/n ... rug-845579

[slayer74]

Eli Lilly Gains After Morgan Stanley Calls It a Top Pick

Investing.com -- Eli Lilly and Company (NYSE:LLY) is trading 3% higher Wednesday after Morgan Stanley analyst Terence Flynn raised the price target on the stock to $364 from $265, maintaining an overweight rating.

The analyst wrote in a note to investors that "LLY has the most robust new product cycle (and hence growth) outlook in Pharma."

Flynn said this is due to the company having the potential to launch five new drugs over the next two years, two of which (Tirzepatide for diabetes and Donanemab for Alzheimer's) they believe could achieve 2030 sales above $5 billion.

The analyst labeled Eli Lilly as his Top Pick.

"If LLY secures FDA approval of Tirzepatide in diabetes, delivers positive Phase 3 obesity data and competitor Phase 3 Alzheimer's data is positive, we would expect LLY's P/E multiple to further expand," concluded Flynn.

https://www.investing.com/news/stock-ma ... ck-2799326

[slayer74]

Eli Lilly (NYSE:LLY) stock rose 1.8% after UBS upgraded its investment stance on the pharma company to ‘buy’ from ‘neutral’, citing the likely benefits of futures sales of a key weight loss drug.

[slayer74]

Eli Lilly prepares for as many as 5 new drug launches next year

(Reuters) -Eli Lilly and Co said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade as it bets on multi-billion dollar markets for treating obesity and Alzheimer's disease.

The drugmaker is spending heavily on marketing and research and development as it prepares for data release and potential approvals for two keenly watched drugs next year, donanemab for Alzheimer's and tirzepatide for obesity.

The higher spending led Lilly to forecast 2023 profit below analysts' estimates and its shares fell about 1% to $363.59. The company's shares have been up about 31% this year.

Tirzepatide received the U.S. health regulator's approval for type 2 diabetes this year and is sold under the brand name Mounjaro.

Lilly expects its marketing and related expenses to be between $6.9 billion and $7.1 billion in 2023, $500 million higher than this year.

"I think we see two of them as kind of generational opportunities, tirzepatide for obesity and donanemab, and the other three as being great opportunities in very competitive spaces," Lilly Chief Executive David Ricks said.

The other three treatments are mirikizumab for a type of inflammatory bowel disease, lebrikizumab for atopic dermatitis and cancer drug pirtobrutinib.

The company also plans to spend between $8.2 billion and $8.4 billion for research and development next year.

Lilly expects revenue between $30.3 billion and $30.8 billion for 2023, higher than Wall Street estimates of $30.12 billion, according to Refinitiv IBES data.

The company forecast 2023 adjusted profit per share of $8.10 to $8.30, lower than analysts' estimates of $9.15.

Lilly expects no sales from its COVID-19 antibody drugs after the U.S. Food and Drug Administration pulled authorization for its therapy bebtelovimab last month.

https://www.investing.com/news/stock-ma ... es-2963196

[slayer74]

Lilly shares slip after FDA rejects early Alzheimer's drug approval

https://www.investing.com/news/stock-ma ... al-2984930

[slayer74]

(Reuters) -Eli Lilly and Co plans to invest an additional $450 million to expand capacity of a plant in North Carolina, the U.S. drugmaker said on Tuesday, as it races to boost production ahead of a decision on its promising obesity treatment.

The company has been struggling to meet strong demand for its incretin products, which include its blockbuster diabetes drug Trulicity and recently launched Mounjaro. Last month, the U.S. Food and Drug Administration added both to its list of drugs facing shortages.

Mounjaro, which has the common name tirzepatide, was approved for diabetes in May last year, and the company anticipates an approval for obesity, a multi-billion dollar market, this year.

Trulicity recorded $5.5 billion in sales last year through Sept. 30, but Lilly and investors have pinned their hopes on Mounjaro to drive future growth.

Goldman Sachs (NYSE:GS) analyst Chris Shibutani, in a note on Monday, estimated the drug would generate sales $2.3 billion in 2023, fueled by rapid uptake, and $27 billion in peak sales in 2032.

The expansion of the Research Triangle Park plant includes additional parenteral filling, device assembly and packaging capacity, Lilly said, adding this phase is expected to create at least 100 new jobs when fully operational in 2027.

"We're on track to achieve the goal we shared in November 2022 of doubling incretin capacity by the end of this year, but this investment is key to ensuring even more patients will have access to medicines they need in the future," Edgardo Hernandez, president of Lilly's manufacturing operations, said in a statement.

Since 2020, the drugmaker has committed $1.7 billion for development and expansion of the Research Triangle Park site.

[slayer74]

Diabetes Behemoth Eli Lilly Slashes Insulin Prices By 70%

https://www.investors.com/news/technolo ... in-prices/

[slayer74]

Jefferies analysts initiated Eli Lilly & Co. (NYSE:LLY) with a Hold rating and $290 price target and Merck & Company Inc (NYSE:MRK) with a Buy rating and $125 price target in separate notes to clients on Monday.

The analysts told investors that LLY at $300 per share is "priced to perfection."

They explained that the stock has "outperformed the DRG" (ARCA Pharmaceutical index) but "at current levels looks 'priced to perfection' as shares bake in success above sell-side #'s."

"While we're bullish on Mounjaro ($40B peak sales) esp T2DM where RR could be unprecedented, for LLY to hit $400/$500, GLP-1 peak sales would need to be $65B & $90B, respectively. We're also cautious on Alzh franchise ($4.3B vs $8.2B) + LTmargins (45% vs 50%) + IRA impact, which needs clarity on before we can see upside," the analysts explained.

They revealed that Merck is the firm's top pharma pick. In addition, they added that the company's $30 billion Keytruda problem is two-thirds solved.

This is due to: "1) Keytruda's LOE looks mismodeled by the street given subQ opportunity, coform., and potential IP upside 2) Sotatercept numbers have upside ($7.5B vs$3.3B) given treatment duration + expansion into other forms of PAH + HF 3)we see MRK hitting its $11B+ target for Gardasil."

jefferies jefferieslogo jefflogo

[slayer74]

Amgen & Eli Lilly upgraded to Overweight at Wells Fargo, Merck downgraded to Equal Weight

Wells Fargo upgraded Amgen (NASDAQ:AMGN) and Eli Lilly (NYSE:LLY) while downgrading Merck (NYSE:MRK).

Amgen was upgraded to Overweight from Equal Weight with a price target of $265.00 (from $275.00) as the firm believes the pessimism related to the company post-Horizon Therapeutics (NASDAQ:HZNP) deal has caused weakness, and it now sees the stock trading approximately 7-8% below the worst-case scenario.

“After combining AMGN-HZNP, we see FV of the company at $247 in a no-Tepezza US growth scenario and modest growth in other parts; the stock is trading below this level. Our base case assumes modest US growth and $5B peak sales for HZNP which is much lower than prior HZNP guidance of $6.5B peak,” said the firm.

Shares gained more than 2% today.

Eli Lilly was upgraded to Overweight from Equal Weight with a price target of $375.00 (from $360.00) as recent weakness creates a buying opportunity.

The firm’s previous Equal Weight thesis was based on unfavorable risk/reward for donanemab Alzheimer's data in H1/23 and the stock being priced to perfection for diabetes/obesity franchise.

Wells Fargo believes that the stock, being down 18% (S&P 500 -5%) without fundamental change, presents a good opportunity, given a good R&D engine, absence of near-to-medium-term loss of exclusivity, and that it is not dependent on M&A for growth.

Shares rose 3% today.

Meanwhile, Merck was downgraded to Equal Weight from Overweight with a price target of $115.00 as the firm believes with the recent appreciation of stock, Merck seems fairly valued at ~16x 2023 PE given that it still has Keytruda-related LOE issues to solve.

Shares fell nearly 2% today.

https://www.investing.com/news/stock-ma ... SI-3029469